Optinose, INC 8-K filings

Paratek Pharmaceuticals has completed its acquisition of Optinose, broadening its commercial portfolio with the addition of XHANCE to its existing antibiotic, NUZYRA.

OptiNose, Inc. stockholders voted to approve the merger agreement with Paratek Pharmaceuticals at a special meeting held on May 16, 2025.

Optinose reports a 13% increase in Q4 XHANCE net revenue and a 23% prescription growth from Q3 to Q4 2024.

OptiNose enters into a definitive agreement to be acquired by Paratek Pharmaceuticals for $9.00 per share in cash plus a contingent value right.

Paratek Pharmaceuticals will acquire Optinose for up to $330 million, aiming to leverage Paratek's commercial infrastructure to expand the reach of XHANCE, a treatment for chronic rhinosinusitis, to primary care providers.

Optinose reported preliminary unaudited net revenue of $22.4 million for XHANCE in the fourth quarter of 2024, with an estimated 20% sequential prescription growth rate.

OptiNose has executed a 1-for-15 reverse stock split, effective December 30, 2024, to increase its share price and maintain Nasdaq listing compliance.

OptiNose stockholders have approved a reverse stock split proposal at a special meeting held on December 23, 2024.

OptiNose reported a 3% increase in XHANCE net revenue for Q3 2024, alongside a positive trend in new prescriptions starting in September, while also adjusting its full-year revenue guidance.

OptiNose, Inc. has received a notice from Nasdaq for failing to maintain a minimum share price of $1.00, putting its listing at risk.

OptiNose, a pharmaceutical company, has appointed Terry Kohler as its new Chief Financial Officer, effective October 7, 2024.

Catherine Owen has resigned from OptiNose's Board of Directors to become the CEO of Acadia Pharmaceuticals.

OptiNose announced its second quarter 2024 financial results, highlighted by a 5% increase in XHANCE net revenue compared to Q2 2023, and narrowed its full-year revenue guidance while increasing its average net revenue per prescription guidance.

OptiNose, Inc. successfully held its 2024 Annual Meeting of Stockholders, re-electing three directors, approving executive compensation, and ratifying its auditor.

OptiNose has extended its manufacturing agreement with Contract Pharmaceuticals Limited Canada (CPL) to December 31, 2026, ensuring continued supply of XHANCE units.

Optinose reported a 26% increase in XHANCE net revenue for Q1 2024 and anticipates positive income from operations in 2025, driven by a recent FDA approval expanding the drug's market.

OptiNose has successfully raised approximately $55 million through a registered direct offering of common stock and pre-funded warrants, led by Nantahala Capital and The D. E. Shaw Group.

Optinose reports preliminary Q1 2024 XHANCE net revenue of $14.9 million and provides a positive outlook following recent FDA approval for chronic sinusitis.

Optinose's XHANCE nasal spray has been approved by the FDA for the treatment of chronic rhinosinusitis without nasal polyps in adults, marking the first such approval for this condition.

OptiNose has received FDA approval for Hikma Pharmaceuticals as an additional manufacturing site for XHANCE, diversifying its supply chain.

OptiNose has amended its debt agreement, adjusting sales targets and make-whole premium terms, providing financial flexibility.

OptiNose announced its fourth quarter and full year 2023 financial results, highlighting a decrease in revenue but also significant cost reductions, while preparing for a potential FDA approval for a new chronic sinusitis indication for XHANCE.

OptiNose US, Inc. has entered into a new three-year office lease in Yardley, PA, with a target commencement date of June 1, 2024.